SmartCrystal combination technology - Scale up from lab to pilot scale and long term stability

Pharmazie

Volumn 65, Issue 12, 2010, Pages 877-884

  Al Shaal, L ^a   Muller R H ^a   Shegokar, Ranjita ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APIGENIN; NANOCRYSTAL;

ARTICLE; LASER DIFFRACTION; MICROSCOPY; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; SCALE UP; ZETA POTENTIAL;

APIGENIN; CRYSTALLIZATION; DRUG STABILITY; ELECTROCHEMISTRY; LASERS; NANOPARTICLES; PARTICLE SIZE; PHOTONS; SPECTRUM ANALYSIS; SUSPENSIONS; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE;

EID: 78650275970     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2010.0181     Document Type: Article

References (45)

1. Agnihotri SM, Vavia PR (2009) Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomed-Nanotechnol Biol Med 5: 90-95.
2. Buckton G, Beezer AE (1992) The Relationship between Particle-Size and Solubility. Int J Pharm 82: R7-R10.
3. Cornard JP, Boudet AC, Merlin JC (2001) Complexes of Al(III) with 3′4′-dihydroxy-flavone: characterization, theoretical and spectroscopic study. Spectrochim Acta A Mol Biomol Spectrosc 57: 591-602.
4. Datta BK, Datta SK, Chowdhury MM, Khan TH, Kundu JK, Rashid MA, Nahar L, Sarker SD (2004) Analgesic, antiinflammatory and CNS depressant activities of sesquiterpenes and a flavonoid glycoside from Polygonum viscosum. Pharmazie 59: 222-225. (Pubitemid 38391429)
5. del Valle JC (2006) Towards a photophysical model for 5-hydroxyflavone. J Chem Phys 124: 104506.
6. Favaro G, Clementi C, Romani A, Vickackaite V (2007) Acidichromism and ionochromism of luteolin and apigenin, the main components of the naturally occurring yellow weld: a spectrophotometric and fluorimetric study. Fluoresc 17: 707-714.
7. Fichera MA, Wissing SA, Müller RH (2004) Effect of 4000 bar homogenisation pressure on particle diminution in drug suspensions. APV, Nürnberg.
8. Ganta S, Paxton JW, Baguley BC, Garg S (2009) Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int J Pharm 367: 179-186.
9. Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L, Zhao W (2008) Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm 355: 321-327.
10. Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K (2005) Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm 299: 167-177. (Pubitemid 40962418)
11. Jeong GS, Lee SH, Jeong SN, Kim YC, Kim EC (2009) Anti-inflammatory effects of apigenin on nicotine- and lipopolysaccharide-stimulated human periodontal ligament cells via heme oxygenase-1. Int Immunopharmacol 9: 1374-1380.
12. Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T (2006) Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release 111: 56-64. (Pubitemid 43289995)
13. Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM (2007) Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 340: 126-133.
14. Kayser O, Kiderlen AF (2003) Delivery strategies for antiparasitics. Expert Opin Investig Drugs 12: 197-207.
15. Keck CM (2008) NanoCrystal® Technology: A formulation approach for poorly water soluble Compounds. Particle Design for APIs and Drug Products. Brussels.
16. Keck CM, Kobierski S, Mauludin R, Müller RH (2008) Second generation of drug nanocrystals for delivery of poorly soluble drugs: smartCrystal technology. Dosis 2: 124-128.
17. Keck CM, Müller RH (2008) Size analysis of submicron particles by laser diffractometry-90% of the published measurements are false. Int J Pharm 355: 150-163.
18. Keck CM, Müller RH (2008) smartCrystals-Review of the Second Generation of Drug Nanocrystals.In: V. P. Torchilin (ed.) Nanoparticlulates as Drug Carriers. London, Imperial College Press.
19. Kerč J, Kobierski S, Keck CM, Müller RH (2009) Influence of different stabilizers on particle size of apigenin nanosuspensions produced by high pressure homogenization. Annual Meeting & Exposition of the Controlled Release Society, Copenhagen, Denmark.
20. Kim HP, Mani I, Iversen L, Ziboh VA (1998) Effects of naturally-occurring flavonoids and biflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea-pigs. Prostag Leukotr Ess 58: 17-24. (Pubitemid 28053786)
21. Krause K, Kayser O, Müller RH, Borner K, Hahn H, Liesenfeld O (2001) Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob Agents Chemothes 45: 1771-1779. (Pubitemid 32466347)
22. Lai F, Sinico C, Ennas G, Marongiu F, Marongiu G, Fadda AM (2009) Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour. Int J Pharm 373: 124-132.
23. Liversidge G (2003) Workshop 'Nanotechnology-solid particles, lipids and nanocomplexes'. IIR Drug Delivery PartnershipsTM Meeting. Cologne/Germany.
24. Mauludin R, Müller RH, Keck CM (2009) Development of an oral rutin nanocrystal formulation. Int J Pharm 370: 202-209.
25. Mishra PR, Al Shaal L, Müller RH, Keck CM (2009) Production and characterization of Hesperetin nanosuspensions for dermal delivery. Int J Pharm 371(1-2): 182-189.
26. Müller RH, Böhm BHL, Grau MJ (1999) Nanosuspensionen: Formulierungen für schwerlösliche Arzneistoffe mit geringer Bioverfügbarkeit. 2. Mitteilung: Stabilität, biopharmazeutische Aspekte, mögliche Arzneiformen und Zulassungsfragen. Pharm. Ind. 61: 175-178.
27. Müller RH, Heinemann S (1993a) Emulsions for Intravenous Administration. I. Emulsions for nutrition and drug delivery.Tharu 2nd 55: 853-856.
28. Müller RH, Heinemann S (1993b) Emulsions for Intravenous Application. II. Destabilisation and stabilisation mechanisms in fat emulsions. Die Pharmazeutische Industrie 55: 948-953.
29. Müller RH, Jacobs C, Kayser O (2000) Nanosuspensions for the Formulation of Poorly Soluble Drugs.In: F. Nielloud and G. Marti-Mestres (ed.) Pharmaceutical Emulsions and Suspensions, Marcel Dekker: 383-407.
30. Müller RH, Junghanns J-U (2006) Drug nanocrystals/nanosuspensions for the delivery of poorly soluble drugs.In: V. P. Torchilin (ed.) Nanoparticulates as Drug Carriers. London, Imperial College Press: 307-328.
31. Müller RH, Keck CM, Petersen RD (2008) Rutin smartCrystals: Bioactivity enhancement and stability against electrolytes. Annual Meeting of the American Association of Pharmaceutical Scientists (AAPS), Atlanta, USA.
32. Perez-Vizcaino F, Bishop-Bailley D, Lodi F, Duarte J, Cogolludo A, Moreno L, Bosca L, Mitchell JA, Warner TD (2006) The flavonoid quercetin induces apoptosis and inhibits JNK activation in intimal vascular smooth muscle cells. Biochem Biophys Res Commun 346: 919-925. (Pubitemid 44192515)
33. PetersenRD(2006) Nanocrystals for use in topical formulations and method of production thereof. PCT/EP2007/009943. Germany, Abbott GmbH, Petersen, R.D.
34. Peterson J, Dwyer J (1998) Flavonoids: Dietary occurrence and biochemical activity. Nutrition Res 18: 1995-2018.
35. Rabinow BE (2004) Nanosuspensions in drug delivery. Nat Rev Drug Discov 3: 785-796.
36. Riddick TM (1968) Control of colloid stability through zeta potential; with a closing chapter on its relationship to cardiovascular disease. Wynnewood, Pa., Published for Zeta-Meter, inc.
37. Romanova D, Vachalkova A, Cipak L, Ovesna Z, Rauko P (2001) Study of antioxidant effect of apigenin, luteolin and quercetin by DNA protective method. Neoplasma 48: 104-107. (Pubitemid 32428540)
38. Siddique YH, AfzalM(2009) Antigenotoxic effect of apigenin against mitomycin C induced genotoxic damage in mice bone marrow cells. Food Chem Toxicol 47: 536-539.
39. Stegemann S, Leveiller F, Franchi D, de Jong H, Linden H (2007) When poor solubility becomes an issue: From early stage to proof of concept. Eur J Pharm Sci 31: 249-261. (Pubitemid 47079001)
40. Teeranachaideekul V, Junyaprasert VB, Souto EB, Müller RH (2008) Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology. Int J Pharm 354: 227-234.
41. Van Eerdenbrugh B, Van den Mooter G, Augustijns P (2008) Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 364: 64-75.
42. VanAcker SA, vandenBerg DJ, Tromp MN, Griffioen DH, VanBennekom WP, VanderVijgh WJ, Bast A (1996) Structural aspects of antioxidant activity of flavonoids. Free Radical Bio Med 20: 331-342.
43. Wang WQ, Heideman L, Chung CS, Pelling JC, Koehler KJ, Birt DF (2000) Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines. Mol Carcinogen 28: 102-110. (Pubitemid 30432478)
44. Yi LT, Li JM, Li YC, Pan Y, Xu Q, Kong LD (2008) Antidepressant-like behavioral and neurochemical effects of the citrus-associated chemical apigenin. Life Sci 82: 741-751.
45. Yin F, Giuliano AE, Van Herle AJ (1999) Growth inhibitory effects of flavonoids in human thyroid cancer cell lines. Thyroid 9: 369-376.